RCS - Destiny Pharma PLC - Treatment of XF-73 Nasal reduces antibiotic use

Destiny PharmaAnnouncement

22/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240722:nRSV1790Xa&default-theme=true

RNS Number : 1790X  Destiny Pharma PLC  22 July 2024

Destiny Pharma plc
("Destiny Pharma" or "the Company")

 

Cardiac surgery patients treated with XF-73 Nasal gel require significantly
fewer post-surgical antibiotics

 

Further data from Phase 2b study to be presented at ID Week, a leading US
infectious disease conference

 

Brighton, United Kingdom - 22 July 2024 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life threatening
infections, today announced that new clinical data from its Phase 2b clinical
trial on XF-73 in cardiac surgery patients has been accepted for presentation
at the ID Week conference, the joint annual meeting of the Infectious
Diseases Society of America and the Society for Healthcare Epidemiology of
America on the 16-19 October 2024 in Los Angeles, USA.

 

The title of the presentation is, 'Impact of Exeporfinium Chloride (XF-73)
Nasal Gel on the Use of Post-Operative Anti-staphylococcal Antibiotics in
Cardiovascular Surgery Patients: Results from a Randomised, Placebo-Controlled
Phase 2 Study.'

 

Previously, the Company reported on achieving the primary endpoint for XF-73
Nasal gel, i.e. >99% reduction in nasal S. aureus compared to placebo one
hour before open heart surgery, (p < 0.0001), Mangino et al. 2023(1).

 

Further planned data analysis of a secondary endpoint within the clinical
trial investigated the use by physicians of post-surgical systemic antibiotics
prescribed >48 hours after surgery. Significantly fewer patients in the
XF-73 treatment arm received post-operative anti-staphylococcal antibiotics:
46.5% (20 of a total population of 43), compared to 70% (28 of a total
population of 40) in the placebo group, p=0.045, which suggests that
antibiotics may have been prescribed as an early intervention in more patients
in the placebo arm.

 

The observed reduction of the use of post-operative antibiotics in the XF-73
arm is consistent with the principles of good antimicrobial stewardship which
are crucial for managing and preventing infections more effectively and for
maintaining the efficacy of antibiotics, reducing healthcare complications,
and improving patient safety.

 

Additional advantages of the XF-73 Nasal gel include the short, 24 hour,
pre-surgical dosing regimen, rapidity of S. aureus nasal decolonisation,
remote likelihood of resistance emergence, and the duration of effect. These
features provide a good fit with clinical practice, potentially enabling
infection risk reduction peri-operatively, enhancing flexibility for
scheduling surgeries, and augmenting antibiotic stewardship efforts. Phase 3
studies are being planned to evaluate and gain regulatory approval for XF-73.

 

XF-73 has also demonstrated efficacy against the hospital superbug
methicillin-resistant Staphylococcus aureus (MRSA). In studies published last
year XF-73 was potent against all 840 MRSA strains collected from infected
patients from 33 countries worldwide (Rhys Williams et al. 2023)(2) and was
shown to be up to 1000 times more efficacious than nasal mupirocin (the most
commonly used nasal antibiotic) at treating MRSA in a skin infection model,
(Zhang et al. 2023)(3).

 

Dr Debra Barker, Interim Chief Medical Officer of Destiny Pharma, said: "The
data to be presented at ID Week highlights the ability of XF-73 Nasal gel to
significantly reduce the need for post-surgical antibiotic use. With
antimicrobial resistance continuing to present an existential threat, these
data highlight the value that XF-73 Nasal can provide in meeting this
challenge while delivering favourable patient outcomes."

 

References:

 

1.    Mangino JE, Firstenberg MS, Milewski RKC, et al., 2023. Exeporfinium
chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly
reduced Staphylococcus aureus nasal carriage in cardiac surgery patients:
Safety and efficacy results from a randomized placebo-controlled phase 2
study. Infection Control & Hospital Epidemiology, 2023;44(7):1171-1173.
doi:10.1017/ice.2023.17

2.    William Rhys-Williams, Helen Marie Galvin and William Guy Love, 2023.
Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus
species clinical isolates. Frontiers in Cellular and Infection Microbiology,
2023; 13. doi.org/10.3389/fcimb.2023.1264456

3.    Zhang, C., Li, J., Lu, R., Wang, S., Fu, Z., & Yao, Z., 2023.
Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73),
Against Antibiotic-Resistant Bacteria in Mouse Superficial Skin Infection
Models. Infection and Drug Resistance, 16, 4867-4879.
doi.org/10.2147/IDR.S417231

 

 

For further information, please contact:

 

Destiny Pharma plc
Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com (mailto:destinypharma@fticonsulting.com)

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development pipeline includes
two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA
and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86YTgzNTY4M2FkNmQyNzcyNmJlNWViN2U1MzU0ZjJmN2U6NjoxYWQ4OmYzMjJhZGVkMjlkZTUxYjRlYTI3M2QxNTNjYzkyYmEzZGU0ZGNlMWEzN2E2NjE3YzA5NGFkOTRkZmRjZGUyYjc6cDpG)
.

 

Forward looking statements

Certain information contained in this announcement, including any information
as to the company's strategy, plans or future financial or operating
performance, constitutes "forward-looking statements". These forward looking
statements may be identified by the use of forward-looking terminology,
including the terms "believes", "estimates", "anticipates", "projects",
"expects", "intends", "aims", "plans", "predicts", "may", "will", "seeks"
"could" "targets" "assumes" "positioned" or "should" or, in each case, their
negative or other variations or comparable terminology, or by discussions of
strategy, plans, objectives, goals, future events or intentions. These
forward-looking statements include all matters that are not historical facts.
They appear in a number of places throughout this announcement and include
statements regarding the intentions, beliefs or current expectations of the
Directors concerning, among other things, the company's results of operations,
financial condition, prospects, growth, strategies and the industries in which
the company operates. The Directors of the company believe that the
expectations reflected in these statements are reasonable but may be affected
by a number of variables which could cause actual results or trends to differ
materially. Each forward-looking statement speaks only as of the date of the
particular statement. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future or are beyond the
company's control. Forward looking statements are not guarantees of future
performance. Even if the company's actual results of operations, financial
condition and the development of the industries in which the company operates
are consistent with the forward-looking statements contained in this document,
those results or developments may not be indicative of results or developments
in subsequent periods.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKKLFFZDLZBBV